Candel Therapeutics' new prostate cancer treatment shows significant success in trial, boosting stock 66%.
Candel Therapeutics' CAN-2409 immunotherapy showed significant improvement in disease-free survival when combined with radiation therapy for prostate cancer patients. The Phase 3 trial met its primary endpoint with no new safety concerns, leading to a 66% rise in the company's stock price. If approved, this could offer a new effective treatment option for over 100,000 men diagnosed annually in the U.S.
4 months ago
12 Articles
Articles
Further Reading
You have 12 free stories remaining this month. Subscribe anytime for unlimited access.